Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Intervention Study: Detection of Early Esophageal Neoplastic Lesions by Quantified Fluorescence Molecular Endoscopy Using Oral and Topical Administration of Bevacizumab-800CW and Cetuximab-800CW

NCT05745857 is registered in ClinicalTrials.gov with University Medical Center Groningen as lead sponsor.

NCT NCT05745857
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05745857 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Intervention Study: Detection of Early Esophageal Neoplastic Lesions by Quantified Fluorescence Molecular Endoscopy Using Oral and Topical Administration of Bevacizumab-800CW and Cetuximab-800CW
Lead sponsor
University Medical Center Groningen
Phase
Phase 2
Overall status
Recruiting
Start date
September 15, 2023
Completion date
December 31, 2026
Enrollment
25 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

barrett oesophagitis with dysplasia, barrett's esophagus without dysplasia, esophageal adenocarcinoma